Loading
Prostate Cancer Treatment and Research · Journal article
Molecules · August 14, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of plant extract mechanisms and nutritional interventions in androgen-related disorders (prostate cancer, BPH, androgenetic alopecia, PCOS). It synthesizes preclinical and mechanistic evidence, identifying multi-target anti-androgenic pathways but does not report new clinical trials or definitive efficacy data. The authors call for future standardization, clinical validation, and improved delivery systems.
Narrative review. Conceptual: patients with androgen dysregulation disorders (prostate cancer, benign prostatic hyperplasia, androgenetic alopecia, polycystic ovary syndrome); actual trial populations not reported in abstract..
Plant extracts enriched with polyphenols, alkaloids, and flavonoids target androgen synthesis and androgen receptor signaling across multiple androgen disorder models. Anti-androgenic activity relies on multi-component mixture effects of plant extracts, including crosstalk into cell growth and cycle, anti-inflammatory pathways, and growth factor regulation. Current antiandrogen therapies are constrained by drug resistance, off-target toxicity, and limited long-term efficacy, motivating plant-based alternatives.
In vivo efficacy, human pharmacokinetics, and clinical safety data are not summarized in the provided abstract. Current antiandrogen therapies are constrained by drug resistance, off-target toxicity, and limited long-term efficacy, motivating plant-based alternatives.
Clinicians should recognize that this review identifies theoretical and mechanistic rationales for plant-based anti-androgenic interventions but does not provide clinical evidence sufficient to change current practice. Clinical validation through rigorous trials is explicitly identified as a priority gap.
This is a narrative review synthesizing mechanistic and preclinical evidence on plant extracts and androgen regulation; it identifies research directions rather than reporting new empirical findings or clinical outcomes.
As stated by the source record.
Clinicians should recognize that this review identifies theoretical and mechanistic rationales for plant-based anti-androgenic interventions but does not provide clinical evidence sufficient to change current practice. Clinical validation through rigorous trials is explicitly identified as a priority gap.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Androgen dysregulation impairs the homeostasis of the prostate, hair follicles, and ovaries, driving the pathogenesis of prostate cancer (PCa), benign prostatic hyperplasia (BPH), androgenetic alopecia (AGA), and polycystic ovary syndrome (PCOS). Current antiandrogen therapies are constrained by drug resistance, off-target toxicity, and limited long-term efficacy. Plant extracts, enriched with bioactive constituents such as polyphenols, alkaloids, and flavonoids, represent promising multi-target candidates. Therefore, focusing on plant extracts—particularly those of dietary origin—this review summarized the mechanisms by which they regulate androgen-dependent and androgen-independent signaling pathways, and recent advances in nutritional interventions targeting androgen-responsive organs. Furthermore, it discussed the multi-component combined effects and factors affecting in vivo exposure of plant extracts, including metabolic transformation and tissue distribution, which may influence the anti-androgenic activity. In summary, anti-androgenic plant extracts primarily target androgen synthesis and AR signaling across various androgen disorder models, with crosstalk into cell growth and cycle, anti-inflammatory pathways, and regulation of growth factors. This multi-target regulation relies on the mixture effects of plant extracts. Future research should focus on three directions: extract standardization, clinical validation, and advanced delivery systems.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.